Regulation of IL-6 signaling by miR-125a and let-7e in endothelial cells controls vasculogenic mimicry formation of breast cancer cells
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
The role of tumor-proximal factors in tumor plasticity during chemoresistance and metastasis following chemotherapy is well studied. However, the role of endothelial cell (EC) derived paracrine factors in tumor plasticity, their effect on chemotherapeutic outcome, and the mechanism by which these paracrine factors modulate the tumor microenvironment are not well understood. In this study, we report a novel mechanism by which endothelial miR-125a and let-7e-mediated regulation of interleukin-6 (IL-6) signaling can manipulate vasculogenic mimicry (VM) formation of MDA-MB-231 breast cancer cells. We found that endothelial IL-6 levels were significantly higher in response to cisplatin treatment, whereas levels of IL-6 upon cisplatin exposure remained unchanged in MDA-MB-231 breast cancer cells. We additionally found an inverse correlation between IL-6 and miR-125a/let-7e expression levels in cisplatin treated ECs. Interestingly, IL-6, IL-6 receptor (IL-6R), and signal transducer and activator of transcription 3 (STAT3) genes in the IL-6 pathway are closely regulated by miR-125a and let-7e, which directly target its 3’ untranslated region. Functional analyses revealed that endothelial miR-125a and let-7e inhibit IL-6-induced adhesion of monocytes to ECs. Furthermore, conditioned medium from cisplatin treated ECs induced a significantly higher formation of VM in MDA-MB-231 breast cancer cells as compared to that from intact ECs; this effect of cisplatin treatment was abrogated by concurrent overexpression of miR-125a and let-7e. Overall, this study reveals a novel EC-tumor cell crosstalk mediated by the endothelial miR-125a/let-7e-IL-6 signaling axis, which might improve chemosensitivity and provide potential therapeutic targets for the treatment of cancer.
Abstract
The role of tumor-proximal factors in tumor plasticity during chemoresistance and metastasis following chemotherapy is well studied. However, the role of endothelial cell (EC) derived paracrine factors in tumor plasticity, their effect on chemotherapeutic outcome, and the mechanism by which these paracrine factors modulate the tumor microenvironment are not well understood. In this study, we report a novel mechanism by which endothelial miR-125a and let-7e-mediated regulation of interleukin-6 (IL-6) signaling can manipulate vasculogenic mimicry (VM) formation of MDA-MB-231 breast cancer cells. We found that endothelial IL-6 levels were significantly higher in response to cisplatin treatment, whereas levels of IL-6 upon cisplatin exposure remained unchanged in MDA-MB-231 breast cancer cells. We additionally found an inverse correlation between IL-6 and miR-125a/let-7e expression levels in cisplatin treated ECs. Interestingly, IL-6, IL-6 receptor (IL-6R), and signal transducer and activator of transcription 3 (STAT3) genes in the IL-6 pathway are closely regulated by miR-125a and let-7e, which directly target its 3’ untranslated region. Functional analyses revealed that endothelial miR-125a and let-7e inhibit IL-6-induced adhesion of monocytes to ECs. Furthermore, conditioned medium from cisplatin treated ECs induced a significantly higher formation of VM in MDA-MB-231 breast cancer cells as compared to that from intact ECs; this effect of cisplatin treatment was abrogated by concurrent overexpression of miR-125a and let-7e. Overall, this study reveals a novel EC-tumor cell crosstalk mediated by the endothelial miR-125a/let-7e-IL-6 signaling axis, which might improve chemosensitivity and provide potential therapeutic targets for the treatment of cancer.
참고문헌 (45)
- Abdullah LN, "Mechanisms of chemoresistance in cancer stem cells", Clin Transl Med, 2, pp.3~ (2013)
- Holen KD, "New therapies, new directions : advances in the systemic treatment of metastatic colorectal cancer", Lancet Oncol, 2, pp.290~297 (2001)
- O'Reilly EA, "The fate of chemoresistance in triple negative breast cancer(TNBC)", BBA Clin, 3, pp.257~275 (2015)
- Bleau AM, "PTEN", PI3K, Cell Stem Cell, pp.2009, 4[DOI]
- Zhou W, "Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis", Cancer Cell, 25, pp.501~515 (2014)
- Hanahan D, "The hallmarks of cancer", Cell, 100, pp.57~70 (2000)
- Deanfield JE, "Endothelial function and dysfunction : testing and clinical relevance", Circulation, 115, pp.1285~1295 (2007)
- Lee A, "A PPARgammadependent miR-424", 503-CD40 axis regulates inflammation mediated angiogenesis, 2017, pp.7, 2528~
- 조하늘, "Endothelial miR-26a regulates VEGF-Nogo-B receptor-mediated angiogenesis", BMB Reports, 50(7), pp.384~389 (2017), 생화학분자생물학회
- Butler JM, "Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors", Nat Rev Cancer, 10, pp.138~146 (2010)
- Gilbert LA, "DNA damage-mediated induction of a chemoresistant niche", Cell, 143, pp.355~366 (2010)
- Folberg R, "Vasculogenic mimicry", APMIS, 112, pp.508~525 (2004)
- Kirschmann DA, "Molecular pathways : vasculogenic mimicry in tumor cells : diagnostic and therapeutic implications", Clin Cancer Res, 18, pp.2726~2732 (2012)
- Cao Z, "Tumour vasculogenic mimicry is associated with poor prognosis of human cancer patients : a systemic review and meta-analysis", Eur J Cancer, 49, pp.3914~3923 (2013)
- Wagenblast E, "A model of breast cancer heterogeneity reveals vascular mimicry as a driver of metastasis", Nature, 520, pp.358~362 (2015)
- Hendrix MJ, "Vasculogenic mimicry and tumour-cell plasticity : lessons from melanoma", Nat Rev Cancer, 3, pp.411~421 (2003)
- Williamson SC, "Vascu logenic mimicry in small cell lung cancer", Nat Commun, 7, pp.13322~ (2016)
- Bharti R, "Cancer development, chemoresistance, epithelial to mesenchymal transition and stem cells : A snapshot of IL-6 mediated involvement", Cancer Lett, 375, pp.51~61 (2016)
- Dijkgraaf EM, "Interleukin-6", interleukin-6 receptor pathway as a new therapy target in epithelial ovarian cancer, 2012, pp.18, 3816~3827
- Rossi JF, "Interleukin-6 as a therapeutic target", Clin Cancer Res, 21, pp.1248~1257 (2015)
- Wang Y, "Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells", Cancer Lett, 295, pp.110~123 (2010)
- Hong L, "MicroRNA-200c Represses IL-6, IL-8, and CCL-5 Expression and Enhances Osteogenic Differentiation", PLoS One, 11, pp.e0160915~ (2016)
- Zhang W, "Micro-RNA-181b regulates endotoxin tolerance by targeting IL-6in macrophage RAW264.7 cells", J Inflamm (Lond), 12, pp.18~ (2015)
- Hunter CA, "IL-6 as a keystone cytokine in health and disease", Nat Immunol, 16, pp.448~457 (2015)
- Kanda T, "Interleukin-6 and cardiovascular diseases", Jpn Heart J, 45, pp.183~193 (2004)
- Chen SC, "Herbal remedy magnolol suppresses IL-6-induced STAT3activation and gene expression in endothelial cells", Br J Pharmacol, 148, pp.226~232 (2006)
- Zhang GJ, "Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma", Anticancer Res, 19, pp.1427~1432 (1999)
- Nakashima J, "Serum interleukin 6 as a prognostic factor in patients with prostate cancer", Clin Cancer Res, 6, pp.2702~2706 (2000)
- Seymour JF, "Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma", J Clin Oncol, 13, pp.575~582 (1995)
- Jansson MD, "MicroRNA and cancer", Mol Oncol, 6, pp.590~610 (2012)
- 김종민, "MicroRNAs as critical regulators of the endothelial to mesenchymal transition in vascular biology", BMB Reports, 51(2), pp.65~72 (2018), 생화학분자생물학회
- 이아람, "Therapeutic implications of microRNAs in pulmonary arterial hypertension", BMB Reports, 47(6), pp.311~317 (2014), 생화학분자생물학회
- Kang H, "Negative regulation of NOD1 mediated angiogenesis by PPARgamma-regulated miR-125a", Biochem Biophys Res Commun, 482, pp.28~34 (2017)
- Li Z, "IGF1", IGF1R and micro-RNA let-7e down-regulate each other and modulate proliferation and migration of colorectal cancer cells, 2018, pp.17, 1212~1219
- Shan Y, "MicroRNA-33a and let-7e inhibit human colorectal cancer progression by targeting ST8SIA1", Int J Biochem Cell Biol, 90, pp.48~58 (2017)
- Xiao M, "Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair", J Ovarian Res, 10, pp.24~ (2017)
- Zhu WY, "Differential expression of miR-125a-5p and let-7e predicts the progression and prognosis of non-small cell lung cancer", Cancer Invest, 32, pp.394~401 (2014)
- Huang P, "Down-Regulated miR-125a-5p Promotes the Reprogramming of Glucose Metabolism and Cell Malignancy by Increasing Levels of CD147 in Thyroid Cancer", Thyroid, 28, pp.613~623 (2018)
- Naidu S, "PDGFR-modulated miR-23b cluster and miR-125a-5p suppress lung tumorigenesis by targeting multiple components of KRAS and NF-kB pathways", Sci Rep, 7, pp.15441~ (2017)
- Lu G, "Reduced miR-125a levels associated with poor survival of patients with hepatocellular cancer", Oncol Lett, 14, pp.5952~5958 (2017)
- McCall MN, "MicroRNA profiling of diverse endothelial cell types", BMC Med Genomics, 4, pp.78~ (2011)
- Sun M, "MicroRNA-125a suppresses cell migration, invasion, and regulates hyaluronic acid synthase 1 expression by targeting signal transducers and activators of transcription 3 in renal cell carcinoma cells", J Cell Biochem, 120, pp.1894~1902 (2019)
- Zhang Y, "Let-7e inhibits TNF-alpha expression by targeting the methyl transferase EZH2 in DENV2-infected THP-1 cells", J Cell Physiol, 233, pp.8605~8616 (2018)
- Schnegg CI, "Induction of Vasculogenic Mimicry Overrides VEGF-A Silencing and Enriches Stem-like Cancer Cells in Melanoma", Cancer Res, 75, pp.1682~1690 (2015)
- van der Schaft DW, "Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells", J Natl Cancer Inst, 96, pp.1473~1477 (2004)